Potential use of vaccines in the primary prevention of breast cancer in high-risk patients

Breast Care

Volumn 7, Issue 4, 2012, Pages 281-287

  Lazzeroni, Matteo ^a   Serrano, Davide ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer prevention; Vaccines

Indexed keywords

ALPHA LACTALBUMIN; BCG VACCINE; CANCER VACCINE; COLONY STIMULATING FACTOR; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MELANOMA ANTIGEN; MUCIN 1; PROLACTIN;

BREAST CANCER; BREAST EPITHELIUM; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER TEST; CARCINOGENESIS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHENOTYPE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; TRANSGENIC MOUSE;

EID: 84866917319     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000342167     Document Type: Review

References (75)

1. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991;3-11.
2. Roush SW, Murphy TV: Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-2163.
3. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915.
4. Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267- 296.
5. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012;Epub ahead of print.
6. Pertschuk LP, Axiotis CA, Feldman JG, Kim YD, Karavattayhayyil SJ, Braithwaite L: Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 1999;5:369-374.
7. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, Bersani S, Gobbo S, Eccher A, Chilosi M, Bonetti F: Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009;131:678-682.
8. Lee S, Jung W, Hong SW, Koo JS: Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution study. J Korean Med Sci 2011;26:1001-1006.
9. Perou CM, Jeffrey SS, van de RM, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869- 10874.
11. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE: Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003;39:622-630.
12. Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R: The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-2327.
13. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001;37:1514-1522.
14. Horimoto Y, Tokuda E, Arakawa A, Kosaka T, Saito M, Kasumi F: Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res 2011;167:e205-e210
15. Liao N, Zhang GC, Liu YH, Li XR, Yao M, Xu FP, Li L, Wu YL: HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 2011;207:1-7.
16. Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B: Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years. Oncologist 2009;14:201-212.
17. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-625.
18. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S: Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 2008;105:1650- 1655.
19. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M: Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/ Th1 responses and CD8 T cells through crosspriming. Proc Natl Acad Sci U S A 2007;104:8947- 8952.
20. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ: The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005;106:167-174.
21. Cronwright G, Le BK, Gotherstrom C, Darcy P, Ehnman M, Brodin B: Cancer/testis antigen expression in human mesenchymal stem cells: downregulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65:2207-2215.
22. Yawata T, Nakai E, Park KC, Chihara T, Kumazawa A, Toyonaga S, Masahira T, Nakabayashi H, Kaji T, Shimizu K: Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 2010;49:532-544.
23. Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, Park JH, Nishidate T, Daigo Y, Nakamura Y: Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol 2009;35:673-681.
24. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jager D, Knuth A, Moch H: NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 2007;120:2411-2417.
25. Bandic D, Juretic A, Sarcevic B, Separovic V, Kujundzic-Tiljak M, Hudolin T, Spagnoli GC, Covic D, Samija M: Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 2006;47:32-41.
26. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de BD, Wadle A, Neumann F, Schmidt W, Renner C, Pfreundschuh M: Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006;118:696-703.
27. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M: NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004;64:2199-2204.
28. Taylor M, Bolton LM, Johnson P, Elliott T, Murray N: Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res 2007;9:R46.
29. Grigoriadis A, Caballero OL, Hoek KS, da SL, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM: CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A 2009;106:13493-13498.
30. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nole F, Rotmensz N, Goldhirsch A: Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 2011;22:98-103.
31. Anders CK, Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;9(suppl 2):S73-S81.
32. Karn T, Pusztai L, Ruckhaberle E, Liedtke C, Muller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gatje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M: Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 2012;48:12-23.
33. Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S, Jungbluth AA: Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother 2011;60:999-1007.
34. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, Zavilevich K, Albukh T, Christos P, Mazumdar M, Pavlick A, Polsky D, Shapiro R, Berman R, Spira J, Busam K, Osman I, Bhardwaj N: Expression of the cancer/ testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun 2007;7:11.
35. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ: NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63: 6076-6083.
36. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
37. He JR, Tang LY, Yu DD, Su FX, Song EW, Lin Y, Wang SM, Lai GC, Chen WQ, Ren ZF: Epstein- Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett 2011;309:128-136.
38. Melana SM, Nepomnaschy I, Hasa J, Djougarian A, Djougarian A, Holland JF, Pogo BG: Detection of human mammary tumor virus proteins in human breast cancer cells. J Virol Methods 2010;163:157- 161.
39. Altundag K, Baptista MZ: Human papilloma virus and breast cancer. Br J Cancer 2006;94:338.
40. Bosch FX: Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin Pharmacother 2011;12:2189-2204.
41. Nieto K, Gissmann L, Schadlich L: Human papillomavirus- specific immune therapy: failure and hope. Antivir Ther 2010;15:951-957.
42. Heng B, Glenn WK, Ye Y, Tran B, Delprado W, Lutze-Mann L, Whitaker NJ, Lawson JS: Human papilloma virus is associated with breast cancer. Br J Cancer 2009;101:1345-1350.
43. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE: High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 2008;99:404- 407.
44. Sarkola M, Rintala M, Grenman S, Syrjanen S: Human papillomavirus DNA detected in breast milk. Pediatr Infect Dis J 2008;27:557-558.
45. Kulka J, Kovalszky I, Svastics E, Berta M, Fule T: Lymphoepithelioma-like carcinoma of the breast: not Epstein-Barr virus-, but human papilloma virus-positive. Hum Pathol 2008;39:298-301.
46. Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE: E6/E7 of HPV type promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle 2007;6:2038-2042.
47. Mendizabal-Ruiz AP, Morales JA, Ramirez- Jirano LJ, Padilla-Rosas M, Moran-Moguel MC, Montoya-Fuentes H: Low frequency of human papillomavirus DNA in breast cancer tissue. Breast Cancer Res Treat 2009;114:189-194.
48. Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, Higashi M, Sagara Y, Yoshinaka H, Tsuji T, Natsugoe S, Douchi T, Eizuru Y, Akiba S: Human papillomavirus detected in female breast carcinomas in Japan. Br J Cancer 2008;99:408-414.
49. De CP, Thioux M, Lebigot I, Sigal-Zafrani B, Salmon R, Sastre-Garau X: No evidence of human papillomavirus DNA sequences in invasive breast carcinoma. Breast Cancer Res Treat 2008;109:55- 58.
50. Choi YL, Cho EY, Kim JH, Nam SJ, Oh YL, Song SY, Yang JH, Kim DS: Detection of human papillomavirus DNA by DNA chip in breast carcinomas of Korean women. Tumour Biol 2007;28: 327-332.
51. Lindel K, Forster A, Altermatt HJ, Greiner R, Gruber G: Breast cancer and human papillomavirus (HPV) infection: no evidence of a viral etiology in a group of Swiss women. Breast 2007;16:172- 177.
52. Wang T, Chang P, Wang L, Yao Q, Guo W, Chen J, Yan T, Cao C: The role of human papillomavirus infection in breast cancer. Med Oncol 2012;29:48-55.
53. Vonka V: Causality in medicine: the case of tumours and viruses. Philos Trans R Soc Lond B Biol Sci 2000;355:1831-1841.
54. Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK: An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 2010;16:799-803.
55. Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J, Cohen EP: Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res 2000;60:2435-2443.
56. Yuan S, Shi C, Liu L, Han W: MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther 2010;10:1037-1048.
57. Yuan S, Shi C, Ling R, Wang T, Wang H, Han W: Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol 2010;136:1359-1367.
58. Lee AK, Rosen PP, DeLellis RA, Saigo PE, Gangi MD, Groshen S, Bagin R, Wolfe HJ: Tumor marker expression in breast carcinomas and relationship to prognosis. An immunohistochemical study. Am J Clin Pathol 1985;84:687-696.
59. Wrba F, Reiner A, Markis-Ritzinger E, Holzner JH, Reiner G, Spona J: Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract 1988;183:277-283.
60. Cohen C, Sharkey FE, Shulman G, Uthman EO, Budgeon LR: Tumor-associated antigens in breast carcinomas. Prognostic significance. Cancer 1987; 60:1294-1298.
61. Nagamatsu Y, Oka T: Purification and characterization of mouse alpha-lactalbumin and preparation of its antibody. Biochem J 1980;185:227-237.
62. Ren J, Stuart DI, Acharya KR: Alpha-lactalbumin possesses a distinct zinc binding site. J Biol Chem 1993;268:19292-19298.
63. Vilotte JL, Soulier S: Isolation and characterization of the mouse alpha-lactalbumin-encoding gene: interspecies comparison, tissue- and stage-specific expression. Gene 1992;119:287-292.
64. Vilotte JL, Soulier S, Mercier JC: Sequence of the murine alpha-lactalbumin-encoding cDNA: interspecies comparison of the coding frame and deduced pre-protein. Gene 1992;112:251-255.
65. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-10582.
66. Guy CT, Cardiff RD, Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-961.
67. Tuohy VK, Jaini R: Prophylactic cancer vaccination by targeting functional non-self. Ann Med 2011;43:356-365.
68. Bailey AJ, Sloane JP, Trickey BS, Ormerod MG: An immunocytochemical study of alpha-lactalbumin in human breast tissue. J Pathol 1982;137:13- 23.
69. Martin RH, Glass MR, Chapman C, Wilson GD, Woods KL: Suppression by bromocriptine of the serum lactalbumin peak associated with human lactogenesis. Clin Endocrinol (Oxf) 1981;14:363-366.
70. Kwon YJ, James E, Shastri N, Frechet JM: In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pHresponsive microparticles. Proc Natl Acad Sci U S A 2005;102:18264-18268.
71. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout- Kuijer MA, van de GG, Fokkink RG, Lambeck AJ, Figdor CG: Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011;118:6836-6844.
72. Tacken PJ, de V, I, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802.
73. Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von MG, Vogel V, Zwierzina H: Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011;12:496-503.
74. Goss PE, Ingle JN, es-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381-2391.
75. Watson CJ, Gusterson BA: A prophylactic vaccine for breast cancer? Breast Cancer Res 2012;12:310.